SIRPA and neoplasm: Based on the role of the CD47-SIRPα axis as a regulator of tumor cell fate, a series of molecules that block the CD47-SIRPα axis are currently under clinical development for tumor indications, and in some cases have encouraging clinical outcomes [5].